PACIRA BIOSCIENCES, INC. Operating Expenses
PACIRA BIOSCIENCES, INC. (PCRX) reported Operating Expenses of $120.71 million for the 3-month period ending 2019-12-31, per its 10-K filed 2020-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-02-21
- PACIRA BIOSCIENCES, INC. operating expenses for the quarter ending 2019-12-31 was $120.71M, a 45.69% increase year-over-year.
- PACIRA BIOSCIENCES, INC. operating expenses for the quarter ending 2019-09-30 was $102.27M, a 28.81% increase year-over-year.
- PACIRA BIOSCIENCES, INC. operating expenses for the quarter ending 2019-06-30 was $97.33M, a 25.48% increase year-over-year.
- PACIRA BIOSCIENCES, INC. operating expenses for the quarter ending 2019-03-31 was $90.23M, a 10.66% increase year-over-year.
- PACIRA BIOSCIENCES, INC. operating expenses for fiscal 2019 was $410.55M, a 27.75% increase from fiscal 2018.
- PACIRA BIOSCIENCES, INC. operating expenses for fiscal 2018 was $321.36M, a 3.14% increase from fiscal 2017.
- PACIRA BIOSCIENCES, INC. operating expenses for fiscal 2017 was $311.57M, a 1.03% increase from fiscal 2016.
- PACIRA BIOSCIENCES, INC. operating expenses for fiscal 2016 was $308.39M, a 28.74% increase from fiscal 2015.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $120.71M 10-K · filed 2020-02-21 | $222.98M derived: sum of 2 quarters · filed 2020-02-21 | $320.31M derived: sum of 3 quarters · filed 2020-02-21 | $410.55M 10-K · filed 2020-02-21 | |
| 2019-09-30 | $102.27M 10-K · filed 2020-02-21 | $199.60M derived: sum of 2 quarters · filed 2020-02-21 | $289.84M 10-Q · filed 2019-11-08 | $372.69M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2019-06-30 | $97.33M 10-K · filed 2020-02-21 | $187.56M 10-Q · filed 2019-08-08 | $270.42M derived: sum of 3 quarters · filed 2020-02-21 | $349.81M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2019-03-31 | $90.23M 10-K · filed 2020-02-21 | $173.09M derived: sum of 2 quarters · filed 2020-02-21 | $252.49M derived: sum of 3 quarters · filed 2020-02-21 | $330.05M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-12-31 | $82.85M 10-K · filed 2020-02-21 | $162.25M derived: sum of 2 quarters · filed 2020-02-21 | $239.82M derived: sum of 3 quarters · filed 2020-02-21 | $321.36M 10-K · filed 2020-02-21 | |
| 2018-09-30 | $79.40M 10-K · filed 2020-02-21 | $156.97M derived: sum of 2 quarters · filed 2020-02-21 | $238.51M 10-Q · filed 2019-11-08 | $309.12M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-06-30 | $77.57M 10-K · filed 2020-02-21 | $159.11M 10-Q · filed 2019-08-08 | $229.72M derived: sum of 3 quarters · filed 2020-02-21 | $300.63M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-03-31 | $81.54M 10-K · filed 2020-02-21 | $152.16M derived: sum of 2 quarters · filed 2020-02-21 | $223.06M derived: sum of 3 quarters · filed 2020-02-21 | $309.78M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2017-12-31 | $70.61M 10-K · filed 2019-02-28 | $141.52M derived: sum of 2 quarters · filed 2019-02-28 | $228.23M derived: sum of 3 quarters · filed 2019-02-28 | $311.57M 10-K · filed 2020-02-21 | |
| 2017-09-30 | $70.91M 10-K · filed 2019-02-28 | $157.62M derived: sum of 2 quarters · filed 2019-02-28 | $240.95M 10-Q · filed 2018-11-01 | $316.32M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $86.71M 10-K · filed 2019-02-28 | $170.05M 10-Q · filed 2018-08-02 | $245.41M derived: sum of 3 quarters · filed 2019-02-28 | $334.63M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $83.33M 10-K · filed 2019-02-28 | $158.70M derived: sum of 2 quarters · filed 2019-02-28 | $247.92M derived: sum of 3 quarters · filed 2019-02-28 | $324.00M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $75.36M 10-K · filed 2018-02-28 | $164.58M derived: sum of 2 quarters · filed 2018-02-28 | $240.67M derived: sum of 3 quarters · filed 2018-02-28 | $308.39M 10-K · filed 2019-02-28 | |
| 2016-09-30 | $89.22M 10-K · filed 2018-02-28 | $165.30M derived: sum of 2 quarters · filed 2018-02-28 | $233.03M 10-Q · filed 2017-11-08 | $303.17M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-06-30 | $76.08M 10-K · filed 2018-02-28 | $143.81M 10-Q · filed 2017-08-02 | $213.94M derived: sum of 3 quarters · filed 2018-02-28 | $271.05M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-03-31 | $67.73M 10-K · filed 2018-02-28 | $137.86M derived: sum of 2 quarters · filed 2018-02-28 | $194.97M derived: sum of 3 quarters · filed 2018-02-28 | $252.29M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2015-12-31 | $70.13M 10-K · filed 2017-03-01 | $127.24M derived: sum of 2 quarters · filed 2017-03-01 | $184.57M derived: sum of 3 quarters · filed 2017-03-01 | $239.54M 10-K · filed 2018-02-28 | |
| 2015-09-30 | $57.10M 10-K · filed 2017-03-01 | $114.43M derived: sum of 2 quarters · filed 2017-03-01 | $169.41M 10-Q · filed 2016-11-02 | $372.24M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $57.33M 10-K · filed 2017-03-01 | $112.31M 10-Q · filed 2016-08-04 | $315.14M derived: sum of 3 quarters · filed 2017-03-01 | $368.17M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $54.98M 10-K · filed 2017-03-01 | $257.81M derived: sum of 2 quarters · filed 2017-03-01 | $310.84M derived: sum of 3 quarters · filed 2017-03-01 | $360.85M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $202.83M 10-K · filed 2017-03-01 | $53.87M 10-K · filed 2015-02-24 | $255.87M derived: sum of 2 quarters · filed 2017-03-01 | $305.87M derived: sum of 3 quarters · filed 2017-03-01 | $202.83M 10-K · filed 2016-02-25 |
| 2014-09-30 | $53.03M 10-K · filed 2016-02-25 | $103.04M derived: sum of 2 quarters · filed 2016-02-25 | $148.96M 10-Q · filed 2015-10-27 | $192.34M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-06-30 | $50.01M 10-K · filed 2016-02-25 | $95.93M 10-Q · filed 2015-07-30 | $139.31M derived: sum of 3 quarters · filed 2016-02-25 | $175.38M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-03-31 | $45.92M 10-K · filed 2016-02-25 | $89.30M derived: sum of 2 quarters · filed 2016-02-25 | $125.38M derived: sum of 3 quarters · filed 2016-02-25 | $154.53M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2013-12-31 | $43.38M 10-K · filed 2015-02-24 | $79.46M derived: sum of 2 quarters · filed 2015-02-24 | $108.61M derived: sum of 3 quarters · filed 2015-02-24 | $138.84M 10-K · filed 2016-02-25 | |
| 2013-09-30 | $36.07M 10-K · filed 2015-02-24 | $65.22M derived: sum of 2 quarters · filed 2015-02-24 | $95.46M 10-Q · filed 2014-10-30 | $121.73M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-06-30 | $29.15M 10-K · filed 2015-02-24 | $59.38M 10-Q · filed 2014-07-31 | $85.66M derived: sum of 3 quarters · filed 2015-02-24 | $109.85M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-03-31 | $30.23M 10-K · filed 2015-02-24 | $56.51M derived: sum of 2 quarters · filed 2015-02-24 | $80.70M derived: sum of 3 quarters · filed 2015-02-24 | $99.67M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2012-12-31 | $26.28M 10-K · filed 2014-02-25 | $50.47M derived: sum of 2 quarters · filed 2014-02-25 | $69.44M derived: sum of 3 quarters · filed 2014-02-25 | $88.38M 10-K · filed 2015-02-24 | |
| 2012-09-30 | $24.19M 10-K · filed 2014-02-25 | $43.16M derived: sum of 2 quarters · filed 2014-02-25 | $62.10M 10-Q · filed 2013-10-31 | $81.05M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-06-30 | $18.97M 10-K · filed 2014-02-25 | $37.91M 10-Q · filed 2013-08-06 | $56.86M derived: sum of 3 quarters · filed 2014-02-25 | $69.55M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-03-31 | $18.94M 10-K · filed 2014-02-25 | $37.89M derived: sum of 2 quarters · filed 2014-02-25 | $50.58M derived: sum of 3 quarters · filed 2014-02-25 | $62.75M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2011-12-31 | $18.95M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $31.64M derived: sum of 2 quarters · filed 2014-02-25 | $43.81M derived: sum of 3 quarters · filed 2014-02-25 | $54.79M 10-K · filed 2014-02-25 | |
| 2011-09-30 | $12.69M 10-Q · filed 2012-11-01 | $24.86M derived: sum of 2 quarters · filed 2012-11-01 | $35.84M 10-Q · filed 2012-11-01 | $44.04M derived: sum of 4 quarters · filed 2013-03-07 | |
| 2011-06-30 | $12.17M 10-Q · filed 2012-08-09 | $23.15M 10-Q · filed 2012-08-09 | $31.35M derived: sum of 3 quarters · filed 2013-03-07 | $42.34M derived: sum of 4 quarters · filed 2013-03-07 | |
| 2011-03-31 | $10.98M 10-Q · filed 2012-05-09 | $19.19M derived: sum of 2 quarters · filed 2013-03-07 | $30.17M derived: sum of 3 quarters · filed 2013-03-07 | $38.85M derived: sum of 4 quarters · filed 2013-03-07 | |
| 2010-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-07 | $19.18M derived: sum of 2 quarters · filed 2013-03-07 | $27.87M derived: sum of 3 quarters · filed 2013-03-07 | $37.27M 10-K · filed 2013-03-07 | |
| 2010-09-30 | $10.98M 10-Q · filed 2011-10-31 | $19.67M derived: sum of 2 quarters · filed 2011-10-31 | $29.07M 10-Q · filed 2011-10-31 | ||
| 2010-06-30 | $8.68M 10-Q · filed 2011-08-11 | $18.09M 10-Q · filed 2011-08-11 | |||
| 2009-12-31 | $43.55M 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |